Bentley Systems and SMRT Trains Collaborate to Improve Safety and Reliability of Metro Rail Services in Singapore
12.10.2021 04:00:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, and SMRT Trains, the pioneer Mass Rapid Transit (MRT) operator in Singapore, have successfully completed the implementation of a Predictive Decision Support System (PDSS) for Singapore’s North-South and East-West lines, the oldest MRT lines in the country. SMRT Trains’ PDSS, which is based on Bentley’s AssetWise Linear Analytics, contributes to improving the reliability of the two lines across 282 kilometers of track and has helped SMRT Trains achieve more than 1 million kilometers between failure (MKBF). MKBF is a measure of reliability used by train operators around the world, where a failure is defined as a service delay of more than five minutes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005442/en/
Kaushik Chakraborty, vice president, Bentley Asia South, and Gan Boon Jin, president of Strides Engineering, at the MOU signing ceremony. (Photo: Business Wire)
Based on the success of the PDSS implementation on the North-South and East-West lines, SMRT Trains has started the implementation of the PDSS solution on the Circle Line (CCL) in Singapore.
With many owner-operators of large metro networks in Asia Pacific cities focusing on improving reliability to provide uninterrupted services to riders, Bentley Systems and Strides Engineering, previously SMRT Services, a business arm of SMRT Corporation that provides a range of station-based engineering services, announced the signing of a Memorandum of Understanding (MOU) to jointly market a rail predictive maintenance solution in the Asia Pacific region. The MOU establishes a partnership between the two companies that combines strong technology expertise and rail operational capabilities to help urban rail and metro operators. Under the terms of the MOU, both organizations will market a rail predictive maintenance solution that visualizes all rail asset information and manages, monitors, and analyzes rail conditions. Bentley Systems will continue to sell, implement, and support its AssetWise solution while Strides Engineering will market and deliver its domain experience and add-on applications for track maintenance.
SMRT Trains will be featured in an Infrastructure Spotlight Series webinar in November as a part of Bentley Systems’ Year in Infrastructure 2021 presentations highlighting advancements in going digital. Registration details will be available soon for this session on yii.bentley.com to learn more about how SMRT Trains is an innovator to watch.
Lam Sheau Kai, president of SMRT Trains, said, “Leveraging technology and taking pre-emptive actions are two very important components in the plan to help us improve and maintain rail reliability for the train lines SMRT Trains operates. PDSS represents both components, and its successful implementation for the North-South and East-West lines has given us much confidence to scale it for the rest of our lines.”
Commenting on the new partnership, Gan Boon Jin, president of Strides Engineering, said, “Strides Engineering’s collaboration with Bentley Systems on the PDSS demonstrates a firm partnership in combining strong domain and rail operational capabilities with proven technological expertise. The PDSS will enhance and optimize decision-making in rail maintenance. We look forward to bringing the best practices and results of PDSS to other train operators in the region.”
Kaushik Chakraborty, vice president, Bentley Asia South, said, “We are extremely happy and honored to partner with Strides Engineering to forward our common objective of advancing infrastructure. With our combined strengths and industry experience, we will empower rail and metro operators in the region to improve reliability of the infrastructure that serves citizens and residents.”
##
About SMRT Trains
SMRT Trains Ltd is the first and largest train services provider in Singapore. As a subsidiary of SMRT Corporation Ltd, we manage and operate train services on the North-South Line, East-West Line, the Circle Line, the new Thomson-East Coast Line and the Bukit Panjang Light Rail Transit.
We have set our core values to be Respect, Integrity, Service and Safety, and Excellence. SMRT Trains is committed to provide safe, reliable and comfortable service.
About Strides Engineering
Advanced Innovative Technologies & Digital Solutions
Strides Engineering, a business arm of SMRT Corporation Limited, has deep, proven experience in exploiting advanced innovative technologies as well as digital solutions and services to deliver safety, reliability, and comfort for commuters.
About Bentley Systems
Bentley Systems (Nasdaq:BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, AssetWise Linear Analytics, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005442/en/
Contact information
Press:
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems
SMRT Corporate Communications
+65 9822 0902
media@smrt.com.sg
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom